An observational study in Rett Syndrome, sponsored by Rett Syndrome Research Trust. Active, not recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Rett Syndrome Research Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.
Among the 55 studies in Rett Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2025, is one of 21 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 45th registered.
96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.
Browse Rett Syndrome studies →11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:
Biomed Industries, Inc. · Sites in United States, Australia
Ages 5–20 · Women only
UCB BIOSCIENCES, Inc. · Sites in United States, Belgium, China and 10 more countries
Ages 5–35
University of Rochester · Sites in United States
Ages 2+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–99
Ionis Pharmaceuticals, Inc. · Sites in United States, Austria, Canada and 2 more countries
Ages 2–65 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 14
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 29 observational studies indexed under Rett Syndrome.
Median enrollment 32 across the 34 interventional studies, 146 across the 21 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 55 have an industry lead sponsor. The 10 most frequent:
Rett Syndrome Research Trust is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Rett Syndrome Research Trust has 5 studies filed under Rett Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Rett Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06840496Phase 3Biomed Industries, Inc.To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | 2027-09-30 |
| NCT06338267Rett Syndrome Research TrustValidating Innovative Biosensors for Rett Autonomic Symptom Tracking | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT05012475Georgetown UniversityMeasuring Impact of Computer Gaming on Arm Use in Rett Syndrome | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Rett Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document device use and symptom status, and will come to the clinic for 1 overnight sleep study. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.
The study will provide information on the feasibility and ease of use for families at home, biosensor data will be compared to data collected at the same time from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome, and Emerald will be developed to include movement as a measurable symptom.
Clinical trials in Rett syndrome typically use subjective assessment scales to assess changes in symptoms. These scales require observer interpretation and can be subject to bias and placebo effect. They are often not fit for purpose, are adapted from other disorders, are not properly validated for use in Rett and therefore are not optimal tools to accurately and reliably assess symptom change.
The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in these devices for use in clinical trials. VIBRANT will use several biosensors to collect symptom data from patients with Rett syndrome over 9 weeks. The devices under study include the FDA-cleared VV330 ECG patch for heart rate, Kids O2 pulse oximeter ring for blood oxygen levels; and the non-wearable device Emerald for sleep, breathing, and movement.
To be eligible, participants will have an MECP2 genetic variant considered causative for the disorder. Participants will come to the clinic for Screening for an eligibility assessment and will learn to use the biosensors. Participants will use the biosensors on an intermittent schedule at home for between approximately 4 to 9 weeks, depending on the device, and will come to the clinic for 1 overnight sleep study during the 9-week observation period. All devices will be used during the overnight sleep study. The data collected by the biosensors will be compared to the data collected from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.
The goals of the study are to demonstrate FDA-cleared devices to assess heart rate, breathing, and oxygen saturation can be reliably used in Rett individuals, both adult and pediatric; determine how accurate and reliable the biosensor results are compared to the overnight sleep study, or to other FDA-cleared devices at home; to and to develop Emerald's ability to assess movement.
Participants must have a documented genetic variant in MECP2 considered causative for Rett syndrome, must be generally healthy, able to tolerate device use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who are not in a separate interventional treatment trial
Participants who are also in a separate interventional treatment trial
Assess heart rate variability with Vivalink VV330 ECG patch
Use FDA-cleared Vivalink VV330 patch to directly and objectively measure heart rate parameters
Time frame: 4 weeks
Assess blood oxygen levels with Viatom Kids O2 pulse oximeter ring
Use FDA-cleared Viatom Kids O2 pulse oximeter ring to directly and objectively measure blood oxygen levels
Time frame: 6 weeks
Validate FDA-cleared Vivalink VV330 ECG patch for heart rate variability metrics in Rett syndrome compared to in-lab PSG
Comparison of results from ECG patch to PSG ECG results to determine accuracy and reliability
Time frame: During PSG comparison (1 night)
Validate ECG-derived breathing compared to in-lab PSG
Comparison of results from ECG-derived breathing to PSG breathing results to determine accuracy and reliability
Time frame: During PSG comparison (1 night)
Validate FDA-cleared Viatom Kids O2 pediatric pulse oximeter ring in Rett syndrome compared to in-lab PSG and/or Nonin wristOx pulse oximeter
Comparison of results from pulse oximeter ring to PSG pulse oximeter results to determine accuracy and reliability
Time frame: During PSG comparison (1 night)
Validate Emerald ability to reliably measure breathing and sleep compared to in-lab PSG
Compare Emerald to directly and objectively measure sleep and night time breathing
Time frame: During PSG comparison (1 night)
Validate Emerald ability to reliably measure breathing and sleep at home compared to FDA-cleared comparator
Compare Emerald to FDA-cleared SleepView home sleep test to directly and objectively measure sleep and night time breathing
Time frame: 9 weeks
Develop Emerald ability to measure daytime movement
Compare Emerald signals of movement with video
Time frame: 9 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rett Syndrome Research Trust